Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Donskov · SciRah

Researcher profile · Semantic Scholar

F. Donskov

Share profile

F. Donskov — researcher profile on SciRah

h-index: 61
Works: 332
Citations: 23K

Most-cited papers

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
E. Jonasch, F. Donskov, O. Iliopoulos, W. Rathmell +11 more
2021New England Journal of Medicine541 citations Open access
Semantic Scholar
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
Shaan Dudani, G. de Velasco, J. Wells, C. Gan +16 more
2021JAMA Network Open302 citations Open access
Semantic Scholar
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
R. Motzer, D. McDermott, B. Escudier, M. Burotto +21 more
2022Cancer247 citations Open access
Semantic Scholar
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
S. Pal, R. Uzzo, J. Karam, V. Master +17 more
2022The Lancet210 citations Open access
Semantic Scholar
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
D. McDermott, Jae-Lyun Lee, M. Ziobro, C. Suárez +15 more
2021Journal of Clinical Oncology182 citations Open access
Semantic Scholar
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
R. Motzer, T. Powles, M. Atkins, B. Escudier +16 more
2021JAMA Oncology169 citations Open access
Semantic Scholar
von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance.
M. L. Binderup, M. Smerdel, Line Borgwadt, S. Beck-Nielsen +27 more
2022European Journal of Medical Genetics117 citations Open access
Semantic Scholar
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
Z. Bakouny, T. El Zarif, Shaan Dudani, J. Wells +17 more
2022European Urology106 citations Open access
Semantic Scholar
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
D. McDermott, Jae-Lyun Lee, G. Bjarnason, J. Larkin +16 more
2021Journal of Clinical Oncology106 citations Open access
Semantic Scholar
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
M. Ernst, V. Navani, J. Wells, F. Donskov +16 more
2023European Urology72 citations Open access
Semantic Scholar
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and with an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
L. Albiges, N. Tannir, M. Burotto, D. McDermott +18 more
2021European Urology69 citations Open access
Semantic Scholar
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
B. Rini, S. Signoretti, T. Choueiri, D. McDermott +10 more
2022Journal for ImmunoTherapy of Cancer67 citations Open access
Semantic Scholar
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
R. Motzer, P. Russo, N. Haas, C. Doehn +20 more
2021European Urology61 citations Open access
Semantic Scholar
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
B. Bhindi, J. Graham, J. Wells, Ziad Bakouny +16 more
2020European Urology59 citations
Semantic Scholar
Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
N. Tannir, D. McDermott, B. Escudier, H. Hammers +16 more
202058 citations
Semantic Scholar
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
C. Gan, I. Stukalin, D. Meyers, Shaan Dudani +16 more
2021European Journal of Cancer44 citations Open access
Semantic Scholar
Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial
L. Iisager, J. Ahrenfeldt, F. Donskov, B. Ljungberg +4 more
2024BMC Cancer41 citations Open access
Semantic Scholar
661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
R. Motzer, N. Tannir, D. McDermott, M. Burotto +15 more
2021Annals of Oncology39 citations Open access
Semantic Scholar
Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
C. Gan, Shaan Dudani, J. Wells, F. Donskov +16 more
2021Cancer Medicine38 citations Open access
Semantic Scholar
Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.
N. Tannir, B. Escudier, D. McDermott, M. Burotto +16 more
2024Journal of Clinical Oncology36 citations Open access
Semantic Scholar
Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases
Emma Matzen, L. Bartels, B. Løgstrup, Stine Horskær +2 more
2021Cardio-Oncology35 citations Open access
Semantic Scholar
Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma
J. Henriksen, F. Donskov, M. Waldstrøm, A. Jakobsen +3 more
2020Acta oncologica32 citations Open access
Semantic Scholar
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
J. Graham, J. C. Wells, Shaan Dudani, C. Gan +15 more
2022European Journal of Cancer30 citations
Semantic Scholar
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kosuke Takemura, Audreylie Lemelin, M. Ernst, J. C. Wells +20 more
2024European Urology29 citations Open access
Semantic Scholar
Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials
Lone Gamrath, Tobias Bruun Pedersen, M. V. Møller, L. Volmer +3 more
2025Current Oncology Reports28 citations Open access
Semantic Scholar
Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma.
A. Lalani, Z. Bakouny, Subrina Farah, F. Donskov +3 more
2021JAMA Oncology27 citations Open access
Semantic Scholar
Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).
R. Motzer, S. Tykodi, B. Escudier, S. Oudard +16 more
202027 citations
Semantic Scholar
Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy
J. Henriksen, L. Nederby, F. Donskov, M. Waldstrøm +3 more
2020Journal of Ovarian Research26 citations Open access
Semantic Scholar
Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.
T. Choueiri, B. Escudier, D. McDermott, M. Burotto +16 more
2025Journal of Clinical Oncology25 citations Open access
Semantic Scholar
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kosuke Takemura, M. Ernst, V. Navani, J. C. Wells +16 more
2023European Urology Oncology23 citations
Semantic Scholar
LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection
A. Bex, R. Uzzo, J. Karam, V. Master +16 more
2022Annals of Oncology22 citations Open access
Semantic Scholar
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
V. Navani, J. Wells, D. Boyne, W. Cheung +15 more
2022Clinical Genitourinary Cancer22 citations Open access
Semantic Scholar
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis.
D. Araujo, J. Wells, A. Hansen, N. Dizman +16 more
2021Journal of Geriatric Oncology22 citations
Semantic Scholar
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
V. Navani, M. Ernst, J. C. Wells, T. Yuasa +17 more
2022JAMA Network Open19 citations Open access
Semantic Scholar
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial
B. Escudier, B. Beuselinck, Asim Amin, C. Porta +29 more
202017 citations
Semantic Scholar
The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).
A. Schmidt, Wan-Ling Xie, C. Gan, Connor Wells +16 more
202115 citations
Semantic Scholar
Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
R. Srinivasan, F. Donskov, O. Iliopoulos, W. Rathmell +11 more
202114 citations
Semantic Scholar
Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study
T. A. Horsbøl, S. Dalton, J. Christensen, A. Petersen +5 more
2021Acta oncologica13 citations Open access
Semantic Scholar
Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.
N. Tannir, R. Motzer, L. Albiges, E. Plimack +16 more
202112 citations
Semantic Scholar
Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma
Aska Drljevic-Nielsen, J. Mains, K. Thorup, M. B. Andersen +2 more
2022European Radiology11 citations
Semantic Scholar
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
J. Wells, Shaan Dudani, C. Gan, I. Stukalin +14 more
2021Clinical Genitourinary Cancer11 citations Open access
Semantic Scholar
Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.
D. McDermott, Jae-Lyun Lee, F. Donskov, S. Tykodi +16 more
202011 citations
Semantic Scholar
Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma
Kasper Munch Lauridsen, M. Hokland, S. Al-Karradi, H. Møller +2 more
2022Cancer Immunology and Immunotherapy10 citations Open access
Semantic Scholar
Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
C. Gan, Shaan Dudani, J. Wells, A. Schmidt +16 more
2021Journal of Clinical Oncology10 citations
Semantic Scholar
First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.
Jae-Lyun Lee, M. Ziobro, C. Suárez, Przemyslaw Langiewitz +15 more
202010 citations
Semantic Scholar
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis.
Mehul Gupta, Connor Wells, Meredith M. Regan, Wan-Ling Xie +16 more
2024European Urology Oncology7 citations Open access
Semantic Scholar
CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
V. Navani, Connor Wells, D. Boyne, W. Cheung +16 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar
Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer
T. Berg, Maj-Britt Jensen, M. Rossing, T. Bechmann +3 more
2024JAMA Network Open6 citations Open access
Semantic Scholar
MP45-03 GRADE, AGE, NODES, AND TUMOR (GRANT) COMPARED WITH LEIBOVICH SCORE TO PREDICT SURVIVAL IN LOCALIZED RENAL CELL CARCINOMA: A NATIONWIDE STUDY
Simon Juul, F. Donskov, P. Clark, L. Lund +1 more
20216 citations
Semantic Scholar
Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need
F. Donskov
2021Annals of Translational Medicine6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Choueiri×20
Invite
T. Choueiri — researcher profile on SciRah
T. Powles×18
Invite
T. Powles — researcher profile on SciRah
B. Beuselinck×13
Invite
B. Beuselinck — researcher profile on SciRah
S. Pal×13
Invite
S. Pal — researcher profile on SciRah

×12

Invite

D. Heng — researcher profile on SciRah

D. McDermott×11

Invite

D. McDermott — researcher profile on SciRah

Shaan Dudani×10

Invite

Shaan Dudani — researcher profile on SciRah

C. Kollmannsberger×10

Invite

C. Kollmannsberger — researcher profile on SciRah

Invite

B. Rini — researcher profile on SciRah

Invite

N. Tannir — researcher profile on SciRah

Invite

J. Wells — researcher profile on SciRah

Invite

C. Gan — researcher profile on SciRah